Back to Search
Start Over
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
- Source :
- American Journal of Psychiatry. 177:716-726
- Publication Year :
- 2020
- Publisher :
- American Psychiatric Association Publishing, 2020.
-
Abstract
- New antidepressant treatments are needed that are effective, rapid acting, safe, and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation treatment that has been approved by the U.S. Food and Drug Administration for treatment-resistant depression. Recent methodological advances suggest that the current iTBS protocol might be improved through 1) treating patients with multiple sessions per day at optimally spaced intervals, 2) applying a higher overall pulse dose of stimulation, and 3) precision targeting of the left dorsolateral prefrontal cortex (DLPFC) to subgenual anterior cingulate cortex (sgACC) circuit. The authors examined the feasibility, tolerability, and preliminary efficacy of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), an accelerated, high-dose resting-state functional connectivity MRI (fcMRI)-guided iTBS protocol for treatment-resistant depression.Twenty-two participants with treatment-resistant depression received open-label SAINT. fcMRI was used to individually target the region of the left DLPFC most anticorrelated with sgACC in each participant. Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold (adjusted for cortical depth). Neuropsychological testing was conducted before and after SAINT.One participant withdrew, leaving a sample size of 21. Nineteen of 21 participants (90.5%) met remission criteria (defined as a score11 on the Montgomery-Åsberg Depression Rating Scale). In the intent-to-treat analysis, 19 of 22 participants (86.4%) met remission criteria. Neuropsychological testing demonstrated no negative cognitive side effects.SAINT, an accelerated, high-dose, iTBS protocol with fcMRI-guided targeting, was well tolerated and safe. Double-blinded sham-controlled trials are needed to confirm the remission rate observed in this initial study.
- Subjects :
- Adult
Male
Prefrontal Cortex
Stimulation
Neuropsychological Tests
Gyrus Cinguli
Depressive Disorder, Treatment-Resistant
03 medical and health sciences
Cognition
0302 clinical medicine
Clinical Protocols
medicine
Humans
Monitoring, Physiologic
Psychiatric Status Rating Scales
business.industry
Functional Neuroimaging
Functional connectivity
Remission Induction
medicine.disease
Magnetic Resonance Imaging
Transcranial Magnetic Stimulation
Neuromodulation (medicine)
030227 psychiatry
Psychiatry and Mental health
Brain stimulation
Antidepressant
Female
business
Treatment-resistant depression
Neuroscience
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 15357228 and 0002953X
- Volume :
- 177
- Database :
- OpenAIRE
- Journal :
- American Journal of Psychiatry
- Accession number :
- edsair.doi.dedup.....4ccdfd7bc61b12692cac2f1eca3c1cd5
- Full Text :
- https://doi.org/10.1176/appi.ajp.2019.19070720